04:44 PM EST, 11/13/2025 (MT Newswires) -- TriSalus Life Sciences ( TLSI ) reported a Q3 loss of $0.96 per diluted share, widening from a loss of $0.12 a year earlier.

Analysts polled by FactSet expected a loss of $0.15.

Revenue for the three months ended Sept. 30 was $11.6 million, up from $7.3 million a year earlier.

Analysts surveyed by FactSet expected $11.8 million.

The company reaffirmed its full-year 2025 revenue growth guidance of 50%.